Intellia Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Intellia Therapeutics (NTLA).

Price Target Range — 11 Quarters

Analyst Consensus — 24 Analysts

2S.Buy

13Buy

5Hold

4Sell

Consensus RatingBuy# Analysts24Avg. Consensus PT$25Upside to Avg. PT+89.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 6, 2026	Barclays	Eliana Merle	Initiate	Underweight	$8
Sep 9, 2026	Citizens	Silvan Turkcan	Maintained	Market Outperform	$30
Sep 9, 2026	Wedbush	David Nierengarten	PT Raise	Neutral	$12→$13
Sep 9, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$25
Aug 25, 2026	Citizens	Silvan Turkcan	Maintained	Market Outperform	$30
Aug 7, 2026	Evercore ISI Group	Jonathan Miller	Upgrade	In-Line→Outperform	$16→$24
Jul 16, 2026	Wolfe Research	Andy Chen	Downgrade	Peer Perform→Underperform	$9
Jul 10, 2026	Wedbush	David Nierengarten	PT Raise	Neutral	$12→$17
Jun 16, 2026	Canaccord Genuity	Whitney Ijem	Maintained	Buy	$49
Jun 15, 2026	Citizens	Silvan Turkcan	Maintained	Market Outperform	$30
Jun 15, 2026	Wedbush	David Nierengarten	Maintained	Neutral	$12
Jun 15, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$25
May 13, 2026	Bernstein	William Pickering	PT Raise	Market Perform	$13→$17
May 13, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Cut	Buy	$30→$25
May 12, 2026	Canaccord Genuity	Whitney Ijem	PT Cut	Buy	$58→$49
May 12, 2026	Wedbush	David Nierengarten	Maintained	Neutral	$12
Apr 28, 2026	Canaccord Genuity	Whitney Ijem	PT Raise	Buy	$48→$58
Apr 28, 2026	Goldman Sachs	Salveen Richter	PT Raise	Sell	$8→$9
Apr 28, 2026	Morgan Stanley	Terence Flynn	PT Raise	Equal-Weight	$11→$15
Apr 28, 2026	Citizens	Silvan Turkcan	PT Raise	Market Outperform	$28→$30

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barclays Initiates Coverage On Intellia Therapeutics with Underweight Rating, Announces Price Target of $8

Barclays analyst Gena Wang initiates coverage on Intellia Therapeutics (NASDAQ:NTLA) with a Underweight rating and announces Price Target of $8.

Benzinga Newsdesk

PRO
Citizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target

Citizens analyst Silvan Turkcan reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Market Outperform and maintains $30 price target.

Benzinga Newsdesk

PRO
Wedbush Maintains Neutral on Intellia Therapeutics, Raises Price Target to $13

Wedbush analyst David Nierengarten maintains Intellia Therapeutics (NASDAQ:NTLA) with a Neutral and raises the price target from $12 to $13.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $25 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Buy and maintains $25 price target.

Benzinga Newsdesk

PRO
Citizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target

Citizens analyst Silvan Turkcan reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Market Outperform and maintains $30 price target.

Benzinga Newsdesk

PRO
Evercore ISI Group Upgrades Intellia Therapeutics to Outperform, Raises Price Target to $24

Evercore ISI Group analyst Jonathan Miller upgrades Intellia Therapeutics (NASDAQ:NTLA) from In-Line to Outperform and raises the price target from $16 to $24.

Benzinga Newsdesk

Intellia Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Intellia Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Barclays Initiates Coverage On Intellia Therapeutics with Underweight Rating, Announces Price Target of $8

PRO
Citizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target

PRO
Wedbush Maintains Neutral on Intellia Therapeutics, Raises Price Target to $13

PRO
HC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $25 Price Target

PRO
Citizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target

PRO
Evercore ISI Group Upgrades Intellia Therapeutics to Outperform, Raises Price Target to $24

People Also Watch

People Also Watch

Intellia Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Intellia Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBarclays Initiates Coverage On Intellia Therapeutics with Underweight Rating, Announces Price Target of $8

PROCitizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target

PROWedbush Maintains Neutral on Intellia Therapeutics, Raises Price Target to $13

PROHC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $25 Price Target

PROCitizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target

PROEvercore ISI Group Upgrades Intellia Therapeutics to Outperform, Raises Price Target to $24

People Also Watch

People Also Watch

PRO
Barclays Initiates Coverage On Intellia Therapeutics with Underweight Rating, Announces Price Target of $8

PRO
Citizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target

PRO
Wedbush Maintains Neutral on Intellia Therapeutics, Raises Price Target to $13

PRO
HC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $25 Price Target

PRO
Citizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target

PRO
Evercore ISI Group Upgrades Intellia Therapeutics to Outperform, Raises Price Target to $24